AE11615
Packsize | Purity | Availability | Price | Discounted Price | Quantity | |
---|---|---|---|---|---|---|
100mg | 97% | in stock | $16.00 | $12.00 | - + | |
250mg | 97% | in stock | $31.00 | $22.00 | - + | |
1g | 97% | in stock | $55.00 | $39.00 | - + | |
5g | 97% | in stock | $211.00 | $148.00 | - + | |
10g | 97% | in stock | $422.00 | $296.00 | - + | |
25g | 97% | in stock | $850.00 | $595.00 | - + |
*All products are for research use only and not intended for human or animal use.
*All prices are in USD.
Catalog Number: | AE11615 |
Chemical Name: | 5-Bromo-3,4-dihydroisoquinolin-1(2h)-one |
CAS Number: | 1109230-25-2 |
Molecular Formula: | C9H8BrNO |
Molecular Weight: | 226.0699 |
MDL Number: | MFCD11847788 |
SMILES: | O=C1NCCc2c1cccc2Br |
Complexity: | 195 |
Covalently-Bonded Unit Count: | 1 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 1 |
Hydrogen Bond Donor Count: | 1 |
XLogP3: | 1.9 |
5-Bromo-3,4-dihydroisoquinolin-1(2H)-one, also known as $name$, is a versatile chemical compound widely utilized in chemical synthesis processes. Its main application lies in its role as a valuable building block for the synthesis of various biologically active molecules and pharmaceutical compounds.$name$ serves as a key intermediate in the synthesis of novel heterocyclic compounds, which are essential in drug discovery and development. Its unique structural properties make it a crucial component in the preparation of diverse chemical entities with significant pharmacological potential.In organic synthesis, $name$ is commonly employed as a starting material for the construction of complex molecular structures through various synthetic routes. Its presence facilitates the formation of important functional groups and ring systems, enabling the creation of new compounds with specific desired properties.Overall, the strategic incorporation of $name$ into synthetic pathways enhances the efficiency and effectiveness of chemical synthesis endeavors, contributing to the advancement of pharmaceutical research and the development of new therapeutic agents.